Kim Kunhwa, Chung Tong Han, Etzel Carol J, Kim Jinhyun, Ryu Hyunjin, Kim Dae Won, Hwu Patrick, Hwu Wen-Jen, Patel Sapna P, Liu Mei, Kim Kevin B
The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas Health Science Center at Houston, Houston, TX, USA.
Cancer Epidemiol. 2018 Dec;57:80-84. doi: 10.1016/j.canep.2018.10.003. Epub 2018 Oct 19.
Melanoma and renal-cell carcinoma (RCC) are known to be immunological neoplasms. Previous studies have shown increased risks in patients with melanoma of developing RCC and in those with RCC of developing melanoma. However, data regarding immunocompromised status in these patients are lacking.
We conducted a retrospective review of patients who had a diagnosis of melanoma and/or RCC. Using summary statistics, we calculated total person-years at risk for developing melanoma among patients with RCC and for developing RCC among patients with melanoma, and compared the results with the SEER data. We also assessed medical history related to immune status and the use of immunosuppressive drugs.
Among 13,879 patients with melanoma and 7597 patients with RCC, 89 had diagnoses of both melanoma and RCC (0.6% and 1.2% of melanoma and RCC patients, respectively): eight were diagnosed with both cancers concurrently, 54 were diagnosed with melanoma first, and 27 were diagnosed with RCC first. Standardized incidence ratios (SIRs) were 2.87 (95%CI 2.16-3.74) for developing RCC among the melanoma patients and 2.31 (95%CI 1.52-3.37) for developing melanoma among the RCC patients, compared to age-, sex-, race-, and calendar-specific adjusted incidence rates of each cancer in the SEER registry. None of the 81 patients with sequential diagnoses had a history of immunocompromised disease, nor did they receive chronic immunosuppressive drugs. Only two received chemotherapy and/or radiotherapy.
We demonstrated a strong association between the diagnoses of melanoma and RCC. These increased risks could not be attributed to either immune status or previous antineoplastic treatment.
黑色素瘤和肾细胞癌(RCC)是已知的免疫性肿瘤。既往研究表明,黑色素瘤患者发生RCC以及RCC患者发生黑色素瘤的风险增加。然而,关于这些患者免疫功能低下状态的数据尚缺乏。
我们对诊断为黑色素瘤和/或RCC的患者进行了回顾性研究。使用汇总统计数据,我们计算了RCC患者发生黑色素瘤以及黑色素瘤患者发生RCC的总人年风险,并将结果与监测、流行病学和最终结果(SEER)数据进行比较。我们还评估了与免疫状态相关的病史以及免疫抑制药物的使用情况。
在13879例黑色素瘤患者和7597例RCC患者中,89例同时诊断为黑色素瘤和RCC(分别占黑色素瘤和RCC患者的0.6%和1.2%):8例同时诊断为两种癌症,54例先诊断为黑色素瘤,27例先诊断为RCC。与SEER登记处中每种癌症按年龄、性别、种族和日历特定调整的发病率相比,黑色素瘤患者发生RCC的标准化发病率(SIR)为2.87(95%CI 2.16 - 3.74),RCC患者发生黑色素瘤的标准化发病率为2.31(95%CI 1.52 - 3.37)。81例序贯诊断的患者均无免疫功能低下疾病史,也未接受过慢性免疫抑制药物治疗。仅2例接受过化疗和/或放疗。
我们证明了黑色素瘤和RCC诊断之间存在密切关联。这些增加的风险不能归因于免疫状态或既往抗肿瘤治疗。